“Building upon our biologic therapeutics strategy and following our recent successful M-Scan acquisition, Vitrology now complements the services provided by SGS,” said Chris Kirk, CEO of SGS. “It creates an ideal platform for further deployment in virology and molecular biology, to be leveraged within our Life Science global network.”
At its state-of-the-art GLP/cGMP (Good Laboratory Practices/current Good Manufacturing Practices) laboratory facility, Vitrology provides a comprehensive range of biosafety services such as virology, cell and molecular biology as well as microbiology and electron microscopy. Founded in 2007, privately owned and backed by Archangel Informal Investment, Vitrology has 38 employees with sales agents in North America and Asia. In 2011, it generated revenue in excess of $4.7 million.
Financial terms of the agreement were not disclosed.